ETFs Hold About $4.5 billion of Johnson & Johnson Tuesday, October 5, 7:50 AM ET, by Market News Video Staff ETFChannel.com's "ETF Components" toplist shows that aggregately ETFs hold nearly $4.5 billion of Johnson & ...
ETFs Hold More Than $3.2 Billion of Pfizer Friday, October 8, 7:51 AM ET, by Market News Video Staff According to ETFChannel.com's Top ETF Stock Components list, ETFs hold over $3.2 billion of Pfizer ...
Morgan Stanley Grows More Bullish on JNJ Wednesday, October 20, 11:41 AM ET, by Market News Video Staff This morning, Morgan Stanley raised its EPS estimates on shares of Johnson & Johnson (JNJ) ...
Big Gainers: LNN, AMR, NVO Wednesday, October 20, 5:09 PM ET, by Market News Video Staff Shares of Lindsay Corporation (LNN) are trading higher on Wednesday on news that earnings beat ...
By Market News Video Staff, Wednesday, November 24, 1:08 PM ET
Eli Lilly (NYSE:LLY) and Acrux (ARUXF) announced today the Food and Drug Administration approved their topical testosterone solution Axiron.
The treatment is intended to replace the hormone in men with a testosterone deficiency or absence. Axiron delivers the hormone via an underarm applicator.
The companies estimate that 13 million men over 45 have symptoms associated with low testosterone.
Lilly shares are trading up 0.25% Wednesday.
Eli Lilly is the sixth-largest holding of the Pharmaceuticals HOLDRS (AMEX:PPH) ETF, at 5.41% of the portfolio.
Johnson & Johnson (NYSE:JNJ) is the top stock, at 25.77% of the fund, followed by Pfizer (NYSE:PFE), at 18.16%, and Merck (MRK), at 16.39% of the fund.
Abbott Laboratories (ABT) and Bristol-Myers Squibb (BMY) round out the top five holdings.
This Article's Word Cloud:AMEXARUXFAbbottAdministrationAxironBristolDrugFoodJohnsonLaboratoriesLillyMerckMyersNYSEPfizerPharmaceuticalsSquibbWednesdayabsenceannouncedassociatedcompaniesdeficiencydeliversestimatefivefollowedfundhaveholdingholdingshormoneintendedlargestmillionoverreplaceroundsharessixthstocksymptomstestosteronethattheirtodaytopicaltreatmentunderarmwith
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.